NBIX - Citi starts Neurocrine at neutral sees stock as fairly valued
2023-12-13 15:53:47 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences: Fear Not The IRA
- Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
- Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Neurocrine gets FDA breakthrough therapy status for crinecerfont
- Neurocrine settles all patent disputes related to movement disorder therapy
For further details see:
Citi starts Neurocrine at neutral, sees stock as fairly valued